Clinical Trial Update: Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial update indicates brigatinib is currently recruiting pediatric and young adult patients with ALK-positive Anaplastic Large Cell Lympho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Inflammatory Myofibroblastic Tumor

Drugs mentioned

• brigatinib (Alunbrig) (brigatinib)

Snippet

Sponsor: Princess Maxima Center for Pediatric Oncology | Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor | Phase 1, Phase 2 | Status: RECRUITING